SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2019 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (116)2/16/2019 4:36:39 PM
From: BulbaMan  Respond to of 280
 
Yeah, yours is the sole portfolio holding AXON. The 2/14/19 PR was a bit confusing but the 2/7/19 PR seems to indicate that shareholders of AXON now have the same number of shares in AXGT, which will be traded.
Here’s the relevant bullet point from the 2/7/19 PR:
“Axovant Sciences Ltd. intends to change its name to Axovant Gene Therapies Ltd. and ticker symbol to “AXGT” to reflect its exclusive focus on gene therapies”
finance.yahoo.com

So my inclination is to just substitute AXGT for AXON in your portfolio. But I’m open to change if you or anyone else (e.g., a real world holder of AXON) has better information.
Peace & good health,
Bulba



To: ghmm who wrote (116)2/16/2019 5:20:46 PM
From: rkrw1 Recommendation

Recommended By
ghmm

  Read Replies (1) | Respond to of 280
 
If Arvelle became valuable, the 5% stake would reflect in AXGT share price.
Not sure I would hold my breath on that at least for 2019. :)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News